Kalaris Therapeutics (KLRS): Analyst Price Targets Suggest Substantial Upside from Current Levels

Key Takeaways

• The central $20 target is the arithmetic mean of seven recent, attributable analyst price targets for KLRS, which span a wide $14 to $25 range.
• At the latest verified close of $2.30, reaching $20 would require a very large move of roughly 770%.
• Most targets were set when the stock traded far higher and have not caught up to the sharp decline; independent aggregators report average targets ranging from about $15.50 to $18.75.
• Supporting factors include the differentiated anti-VEGF profile of TH103, Phase 1b/2 data anticipated in the first half of 2027, and roughly $93.5 million in cash.
• Key risks are pre-revenue, clinical-stage binary risk, a data timeline that slipped into 2027, ongoing cash burn, and weak small-cap biotech sentiment.
• For more detail, review the ticker's Major News and Today's Price Move, its Forecast, and upcoming Earnings pages.
• Explore Trending AI Robots to see how AI-driven signals are scanning opportunities across the market.

Understanding the Analyst Consensus for KLRS

Kalaris Therapeutics, Inc. (KLRS) is a clinical-stage biopharmaceutical company, not an ETF. It is developing TH103, an anti-VEGF (vascular endothelial growth factor) treatment for neovascular age-related macular degeneration (nAMD, or "wet" AMD) and other exudative retinal diseases.

For this analysis, seven recent and attributable analyst price targets were reviewed, producing an arithmetic mean of roughly $19.70, rounded to a $20 central target. The range is unusually wide, from a low of $14 to a high of $25. Verifiable entries include Morgan Stanley at $14, Wedbush at $17, Chardan Capital at $19, Citizens JMP and Leerink Partners at $20, Raymond James at $23, and Citizens at $25. An older, stale $3 neutral target from July 2025 was excluded as no longer representative of current fundamentals.

The wide dispersion reflects genuine disagreement about how to value a pre-revenue asset. Independent data providers underscore the uncertainty: TipRanks reports an average near $15.50 based on three recent targets, MarketBeat near $18.75, and S&P Global near $17.67. These figures are context, not a guarantee, and no single target should be read as more likely than another. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

KLRS Current Position and the Road to $20

Shares of KLRS closed at $2.30 on November 9, 2026, giving the company a market capitalization near $55 million. The stock has fallen roughly 72% year to date and about 52% over the past year, sliding from a 52-week high of $11.88 in December 2025 to a low of $1.78 in late October 2026. Reaching $20 would require an upside of about 770% from the current price, a very large move by any standard.

The path would almost certainly hinge on clinical execution rather than near-term financial results, because Kalaris generates no product revenue. Its most advanced program, TH103, is in Phase 1b/2 testing, with preliminary data now expected in the first half of 2027 and potential Phase 3 initiation targeted for year-end 2027. A target this far above the current price effectively assumes successful clinical data and a credible path to commercialization.

What Could Support a Move Toward the Target

The central bull case rests on TH103's design. As a fully humanized recombinant fusion protein that acts as a VEGF "trap," it is engineered to deliver longer-lasting anti-VEGF activity in a large market already served by blockbuster therapies. Positive Phase 1a data reported earlier reinforced visual acuity (BCVA), imaging, and time-to-retreatment findings, and analysts who initiated coverage in 2025 and 2026 cited a potentially differentiated durability profile.

The balance sheet offers some runway. Kalaris reported roughly $93.5 million in cash and reported a net loss of about $11.0 million for the third quarter of 2026. Meaningful insider buying earlier in the period also signaled management confidence. Any clinical de-risking, sector-wide biotech recovery, or analyst target revisions higher could materially narrow the enormous gap between the share price and existing targets.

What Could Prevent the Target From Being Reached

The principal obstacle is binary clinical risk. TH103 has not yet produced Phase 1b/2 data, and a failure or underwhelming readout in 2027 would undermine the entire investment thesis. The data timeline has already slipped, a development that contributed to the stock's decline, and further delays remain possible.

Kalaris is also pre-revenue and will need substantial additional capital before commercialization, exposing shareholders to dilution. Its valuation is entirely forward-looking, so the stock remains highly sensitive to small-cap biotech sentiment, interest-rate expectations, and sector rotation away from risk assets. Finally, because most analyst targets were established at much higher share prices, they carry less near-term informational value and could be revised lower.

Technical Levels and Market Structure

Technically, KLRS remains in a long-term downtrend, trading below its 50-day moving average near $2.66 and its 200-day moving average near $5.18. The $1.78 October low is the key support level, while the $2.50-to-$2.66 zone marks immediate overhead resistance. The psychological $2.00 level has acted as a pivot, and the December 2025 high of $11.88 remains a distant reference point that illustrates how far the stock has fallen.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a research horizon of about 12 months, though individual firms differ, and for a clinical-stage company the effective horizon is driven by the data calendar. Investors should watch the upcoming quarterly results, the timing and content of TH103 Phase 1b/2 data in the first half of 2027, the planned Phase 3 initiation, cash runway disclosures, and any analyst target or rating revisions. Broader moves in biotechnology indices and interest rates will also influence sentiment.

Final Assessment

The question of whether KLRS can reach $20 is, in effect, a question about whether TH103 can succeed clinically. The $20 central target, the mean of seven analyst estimates ranging from $14 to $25, sits about 770% above the latest price of $2.30, a very large gap that reflects both the stock's steep decline and the speculative, binary nature of the asset. Successful Phase 1b/2 data, a timely Phase 3 start, and a favorable financing backdrop could substantially narrow that gap, while disappointing data, further delays, or dilution would make the target far harder to justify. The most important near-term catalyst is the TH103 data readout expected in the first half of 2027, and no definitive outcome can be predicted.

Exploring Tickeron’s AI Daily Buy/Sell Signals

In my research process, I often turn to Tickeron’s AI Daily Buy/Sell Signals to monitor stocks like KLRS. These signals apply artificial intelligence to track thousands of securities and generate Buy, Sell, or Hold recommendations based on technical patterns and market shifts. For a volatile name in the clinical-stage biotech space, this approach can help identify trend changes and manage positions with greater efficiency than manual analysis alone. From what I see, integrating these tools into a broader review of fundamentals and analyst views provides an additional layer of perspective on potential opportunities.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Notable companies

Industry description

Market Cap

High and low price notable news

Volume